AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody
development. Our mission is to cure once incurable diseases such as cancer.
CAR T-cell (Chimeric Antigen Receptor) therapy is the state-of-the-art gene cell therapy that is ushering in the age of
personalized medicine. It boasts superior treatment effectiveness and lower side effects by programming the patient’s
own immune cells to target tumor cells. The first generation of CAR-T treatments have already demonstrated major leaps
in the treatment of patients with hematologic cancers such as leukemia and lymphoma. AbClon’s CAR-T program incorporates
the next-gen technologies of CAR-T by integrating with NEST, zCAR-T, and Affibody platforms.
Antibody drugs act specifically on the target proteins responsible for the disease and as a result have high
efficacy and low side effects. AbClon’s development of the NEST (Novel Epitope Screening Technology) platform
was made possible through its experience in developing tens of thousands of antibodies.
Bispecific antibodies can achieve stronger therapeutic effect by simultaneously acting on two different target
proteins. AbClon’s AffiMab platform allows for easy development of bispecific antibodies by incorporating
Affibody technology. Affibodies are alternative capture molecules one-fifth the size of antibodies that are
affixed to regular antibodies to give it bispecific targeting capability. The AffiMab platform has been integral
towards AbClon’s development of various anti-cancer and autoimmune therapeutics.
AbClon will take the lead in the development of treatments for intractable diseases
based on innovative drug development platforms and its extensive
experience in antibody therapeutics development.